<![CDATA[Celgene Corporation 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=21347>Fri, 01 May 2026 07:13:03 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis]]>https://www.newswire.co.kr/newsRead.php?no=893824Tue, 10 Sep 2019 09:04:48 +0900<![CDATA[FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease]]>https://www.newswire.co.kr/newsRead.php?no=891543Mon, 22 Jul 2019 14:43:12 +0900<![CDATA[US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis]]>https://www.newswire.co.kr/newsRead.php?no=889461Mon, 10 Jun 2019 11:57:17 +0900<![CDATA[Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis]]>https://www.newswire.co.kr/newsRead.php?no=887773Wed, 08 May 2019 09:20:00 +0900<![CDATA[Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma]]>https://www.newswire.co.kr/newsRead.php?no=885808Mon, 01 Apr 2019 12:00:00 +0900<![CDATA[Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis]]>https://www.newswire.co.kr/newsRead.php?no=885444Tue, 26 Mar 2019 10:00:00 +0900<![CDATA[Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis]]>https://www.newswire.co.kr/newsRead.php?no=884737Tue, 12 Mar 2019 10:40:00 +0900<![CDATA[Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients]]>https://www.newswire.co.kr/newsRead.php?no=880890Tue, 18 Dec 2018 11:10:00 +0900<![CDATA[Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018]]>https://www.newswire.co.kr/newsRead.php?no=880031Tue, 04 Dec 2018 10:35:00 +0900<![CDATA[Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018]]>https://www.newswire.co.kr/newsRead.php?no=879966Mon, 03 Dec 2018 14:25:00 +0900<![CDATA[Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session]]>https://www.newswire.co.kr/newsRead.php?no=879964Mon, 03 Dec 2018 13:55:00 +0900<![CDATA[Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018]]>https://www.newswire.co.kr/newsRead.php?no=879957Mon, 03 Dec 2018 13:05:00 +0900<![CDATA[Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018]]>https://www.newswire.co.kr/newsRead.php?no=879956Mon, 03 Dec 2018 11:55:00 +0900<![CDATA[New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018]]>https://www.newswire.co.kr/newsRead.php?no=876856Thu, 11 Oct 2018 15:50:00 +0900<![CDATA[Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint]]>https://www.newswire.co.kr/newsRead.php?no=876689Tue, 09 Oct 2018 10:35:00 +0900<![CDATA[OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone]]>https://www.newswire.co.kr/newsRead.php?no=875503Thu, 13 Sep 2018 10:10:00 +0900<![CDATA[Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia]]>https://www.newswire.co.kr/newsRead.php?no=872145Tue, 10 Jul 2018 11:05:00 +0900<![CDATA[Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018]]>https://www.newswire.co.kr/newsRead.php?no=870278Mon, 04 Jun 2018 14:00:00 +0900<![CDATA[Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma]]>https://www.newswire.co.kr/newsRead.php?no=870262Mon, 04 Jun 2018 11:50:00 +0900<![CDATA[New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting]]>https://www.newswire.co.kr/newsRead.php?no=868261Wed, 25 Apr 2018 11:20:00 +0900<![CDATA[OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers]]>https://www.newswire.co.kr/newsRead.php?no=864710Mon, 19 Feb 2018 11:20:00 +0900<![CDATA[OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis]]>https://www.newswire.co.kr/newsRead.php?no=864706Mon, 19 Feb 2018 11:15:00 +0900<![CDATA[Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting]]>https://www.newswire.co.kr/newsRead.php?no=861304Mon, 11 Dec 2017 09:20:00 +0900<![CDATA[Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma]]>https://www.newswire.co.kr/newsRead.php?no=859960Fri, 17 Nov 2017 09:55:00 +0900<![CDATA[Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting]]>https://www.newswire.co.kr/newsRead.php?no=858730Mon, 30 Oct 2017 10:00:00 +0900